专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08409575B2 Antibodies specific for amyloid beta protofibril 有权
标题翻译：对淀粉样蛋白β原纤维特异的抗体
公开(公告)号：US08409575B2
公开(公告)日：2013-04-02
申请号：US13218592
申请日：2011-08-26
申请人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Näslund
发明人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Näslund
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K14/4711 , A61K38/00 , A61K2039/505
摘要： The invention relates to a purified antibody or fragment thereof that specifically binds an Aβ protofibril. The invention further relates to a composition that includes such antibodies. The invention also relates to using such antibodies and compositions for treating a patient having of suspected of having Alzheimer's disease.
摘要翻译：本发明涉及特异性结合A和Bgr的纯化抗体或其片段; 原纤维本发明还涉及包含这种抗体的组合物。本发明还涉及使用这样的抗体和组合物来治疗怀疑患有阿尔茨海默病的患者。

2. 发明授权

US07700719B2 Arctic β amyloid protofibril 有权
标题翻译：北极和北极淀粉样蛋白原纤维
公开(公告)号：US07700719B2
公开(公告)日：2010-04-20
申请号：US11654508
申请日：2007-01-18
申请人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Näslund
发明人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Näslund
IPC分类号： A61K38/00 , A61K39/00 , A61K39/38 , C07K16/00 , C07K17/00 , C07K5/00
CPC分类号： C07K14/4711 , A61K38/00 , A61K2039/505
摘要： The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunisation against AD.
摘要翻译：本发明涉及阿尔茨海默氏病（AD）的预防和治疗。更具体地，本发明涉及用于治疗或预防AD的目的的用于主动免疫的原始原纤维形成活性的非野生型原纤维或化合物的用途。本发明进一步涉及具有高原纤维形成活性的肽，其具有高的原纤维形成活性以及其几种应用，例如针对所述肽的针对AD的被动免疫的抗体。

3. 发明申请

US20120027755A1 PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE 有权
标题翻译：预防和治疗阿尔茨海默病
公开(公告)号：US20120027755A1
公开(公告)日：2012-02-02
申请号：US13218592
申请日：2011-08-26
申请人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Näslund
发明人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Näslund
IPC分类号： A61K39/395 , A61P25/28 , C07K16/00
CPC分类号： C07K14/4711 , A61K38/00 , A61K2039/505
摘要： The invention relates to a purified antibody or fragment thereof that specifically binds an Aβ protofibril. The invention further relates to a composition that includes such antibodies. The invention also relates to using such antibodies and compositions for treating a patient having of suspected of having Alzheimer's disease.
摘要翻译：本发明涉及特异性结合A和Bgr的纯化抗体或其片段; 原纤维本发明还涉及包含这种抗体的组合物。本发明还涉及使用这样的抗体和组合物来治疗怀疑患有阿尔茨海默病的患者。

4. 发明授权

US07179463B2 Treatment of alzheimer's disease 有权
标题翻译：治疗阿尔茨海默病
公开(公告)号：US07179463B2
公开(公告)日：2007-02-20
申请号：US09899815
申请日：2001-07-09
申请人： Lars Lannfelt , Camilla Nilsberth , Anita Westlind-Danielsson , Jan Näslund
发明人： Lars Lannfelt , Camilla Nilsberth , Anita Westlind-Danielsson , Jan Näslund
IPC分类号： A61K39/395 , A61K39/40 , A61K39/42 , A01N37/18 , C07K16/00
CPC分类号： C07K14/4711 , A61K38/00 , A61K2039/505
摘要： A method for the treatment of Alzheimer's disease in a subject having or suspected of having Alzheimer's disease by administering to the subject a therapeutically effective amount of an antibody wherein the antibody is raised against a protofibril that contains an Aβ-Arc peptide.
摘要翻译：一种通过向受试者施用治疗有效量的抗体，其中所述抗体针对含有Abeta-Arc肽的原纤维起立，用于治疗患有或怀疑患有阿尔茨海默病的受试者中的阿尔茨海默氏病的方法。

5. 发明申请

US20070248606A1 Treatment of Alzheimer's disease 有权
标题翻译：治疗阿尔茨海默病
公开(公告)号：US20070248606A1
公开(公告)日：2007-10-25
申请号：US11654508
申请日：2007-01-18
申请人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Naslund
发明人： Lars Lannfelt , Camilla Nilsberth , Anita Campbell , Jan Naslund
IPC分类号： A61K38/16 , A01K67/00 , A61K39/395 , A61P25/28 , C07H21/00 , C07K16/00 , C12N1/00 , C12N15/00
CPC分类号： C07K14/4711 , A61K38/00 , A61K2039/505
摘要： The present invention relates to prevention and treatment of Alzheimer's disease (AD). More specifically, the invention relates to use of a non-wild type protofibril or compound(s) with protofibril forming activity for active immunisation in the purpose of treating or preventing AD. The invention further relates to a peptide, Aβ-Arc, with high protofibril forming activity as well as several applications thereof, such as antibodies against said peptide for passive immunisation against AD.
摘要翻译：本发明涉及阿尔茨海默氏病（AD）的预防和治疗。更具体地，本发明涉及用于治疗或预防AD的目的的用于主动免疫的原始原纤维形成活性的非野生型原纤维或化合物的用途。本发明还涉及具有高原纤维形成活性的肽Abeta-Arc，以及其几种应用，例如针对所述肽的针对AD的被动免疫的抗体。

6. 发明申请

US20120100129A1 N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders 审中-公开
标题翻译：用于阿尔茨海默病和相关疾病的治疗和诊断方法的N-末端截断的原原纤维/低聚物
公开(公告)号：US20120100129A1
公开(公告)日：2012-04-26
申请号：US13379523
申请日：2010-06-29
申请人： Pär Gellerfors , Lars Lannfelt , Linda Söderberg , Karin Tegerstedt
发明人： Pär Gellerfors , Lars Lannfelt , Linda Söderberg , Karin Tegerstedt
IPC分类号： A61K39/395 , A61P25/28 , G01N33/53 , A61K39/00 , C07K16/18
CPC分类号： C07K16/18 , A61K38/00 , C07K14/4711 , C07K2317/30
摘要： A vaccine for delaying onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual comprises a therapeutically effective amount of a physiologically acceptable protofibril/oligomer comprising N-terminal truncated Aβ. An antibody for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder in an individual binds one or more truncated AO protofibrils/oligomers, but exhibits no or substantially no cross-reactivity with full length Aβ monomers, and optionally said antibody shows cross-reactivity to N-terminal truncated Aβ monomers. Methods for delaying an onset of or for treatment of Alzheimer's disease or an Alzheimer-related disorder employ the vaccine or antibody. Methods of detecting soluble N-terminal truncated amyloid-beta (Aβ) protofibrils/oligomers and N-terminal truncated Aβ monomers employ the antibody.
摘要翻译：用于延迟个体中阿尔茨海默病或阿尔茨海默氏病相关疾病发作或治疗的疫苗包含治疗有效量的包含N-末端截短的A＆bgr的生理上可接受的原纤维/寡聚体。用于延迟个体中阿尔茨海默病或阿尔茨海默病相关病症的发作或治疗的抗体结合一个或多个截短的AO原纤维/寡聚体，但与全长A＆bgr不显示或基本上没有交叉反应性; 单体和任选地所述抗体显示与N-末端截短的A＆bgr的交叉反应性; 单体。用于延迟阿尔茨海默病或阿尔茨海默病相关疾病的发作或治疗的方法使用疫苗或抗体。检测可溶性N-末端截短淀粉样蛋白-β（A＆bgr）原原纤维/寡聚体和N-末端截短的A＆Bgr的方法; 单体使用抗体。

7. 发明申请

US20110052498A1 Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders 有权
标题翻译：用于α-突触核蛋白相关疾病的治疗和诊断方法的抗体和疫苗
公开(公告)号：US20110052498A1
公开(公告)日：2011-03-03
申请号：US12990226
申请日：2009-04-28
申请人： Lars Lannfelt , Joakim Bergström , Martin Ingelsson , Pär Gellerfors
发明人： Lars Lannfelt , Joakim Bergström , Martin Ingelsson , Pär Gellerfors
IPC分类号： A61K49/00 , A61K39/395 , G01N33/53 , C07K16/18 , A61P25/28 , A61P25/18
CPC分类号： A61K51/1018 , A61K38/1709 , C07K16/18 , C07K2317/92 , G01N33/6896 , G01N2333/4709 , Y10S530/839
摘要： A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody.
摘要翻译：用于延迟个体中α-突触核蛋白相关病症的发作或治疗的疫苗包含治疗有效量的分离的稳定的可溶性α-突触核蛋白寡聚体，其具有比非可溶性聚集形式低的形成速率，稳定的α-突触核蛋白的寡聚物。用于延迟个体中α-突触核蛋白相关病症的发作或治疗的抗体结合可溶性α-突触核蛋白。用于延迟治疗或预防α-突触核蛋白相关病症的方法使用疫苗或抗体。 α-突触核蛋白寡聚物检测方法采用抗体。

8. 发明申请

US20070099185A1 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein 审中-公开
标题翻译：用于鉴定调节β-淀粉样蛋白前体蛋白的结构和加工的试剂的方法
公开(公告)号：US20070099185A1
公开(公告)日：2007-05-03
申请号：US10533844
申请日：2003-11-04
申请人： Frederick Hagen , Lars Lannfelt , Par Gellerfors
发明人： Frederick Hagen , Lars Lannfelt , Par Gellerfors
IPC分类号： C40B30/06 , C40B40/08 , C40B40/10
CPC分类号： G01N33/5008 , G01N33/6896 , G01N2333/4709 , G01N2800/2821
摘要： The present invention provides methods for the screening and identification of agents from a large library of molecular structures that can alter the cleavage of amyloid precursor protein (AP). Agents identified by the methods of the present invention that modify the cleavage of APP can be used in the treatment and prevention of Alzheimer's disease. The methods select for and identify effector agents that bind to APP causing a structural change in the structure of APP in such a way that the efficiency of the cleavage of a secretase is modulated. Further, the methods are carried out in an in vivo system that provides for physiological conditions similar or identical to conditions for APP processing. Agents can be selected for their ability to cause a decrease in the amount of B-secretase or β-secretase cleavage of APP, or for an increase in a-secretase cleavage of APP. The agents can be, particularly peptide agents, can be converted into a peptidominetic, an isosteric replacement compound, a D-amino acid analog, or non-peptidyl compound for treating Alzheimer's disease or any other amyloid related or prion related disease. The agents or derivatives thereof can be formulated for intravenous, parenteral, topical, sustained release, intranasal, or inhalation use.
摘要翻译：本发明提供了用于筛选和鉴定可以改变淀粉样蛋白前体蛋白（AP）的切割的大分子结构文库的试剂的方法。通过修饰APP切割的本发明方法鉴定的药剂可用于治疗和预防阿尔茨海默氏病。所述方法选择并鉴定结合APP的效应物，其导致APP结构的结构变化，使得调节分泌酶切割的效率。此外，该方法在体内系统中进行，其提供与APP处理的条件相似或相同的生理条件。可以选择代谢物以降低APP的B-分泌酶或β-分泌酶裂解的量，或者增加APP的分泌酶裂解。药剂可以是特别是肽剂，可以转化为用于治疗阿尔茨海默氏病或任何其他与淀粉样蛋白相关或朊病毒相关疾病的肽基质，异构体替代化合物，D-氨基酸类似物或非肽基化合物。药剂或其衍生物可以配制用于静脉内，肠胃外，局部，持续释放，鼻内或吸入使用。

9. 发明授权

US08404459B2 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 有权
标题翻译：可溶性淀粉样蛋白β原型原纤维特异性抗体及其用途
公开(公告)号：US08404459B2
公开(公告)日：2013-03-26
申请号：US13336520
申请日：2011-12-23
申请人： Pär Gellerfors , Lars Lannfelt
发明人： Pär Gellerfors , Lars Lannfelt
IPC分类号： G01N33/53 , G01N33/542 , G01N33/567
CPC分类号： C07K16/18 , C07K14/4711 , C07K2317/24 , G01N2800/2821 , G01N2800/387
摘要： The invention pertains to a method of measuring Aβ protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype Aβ 42/40 protofibril and Aβ42/40 Arc protofibril and has no or little cross-reactivity to Aβ 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising Aβ protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
摘要翻译：本发明涉及一种测量A＆bgr的方法; 样品中的原纤维。该方法包括以下步骤：（a）提供结合野生型A和bgr的标记的单克隆抗体或其片段; 42/40原纤维和A＆bgr; 42/40弧原纤维，对A＆bgr没有或几乎没有交叉反应性; 42/40单体，其具有产生可测量信号的试剂，（b）使所述标记的抗体或其片段与具有或怀疑包含A＆bgr的流体或组织接触; 原纤维，（c）通过测量由该药剂产生的信号来测量与抗体结合的原纤维的量。

10. 发明授权

US08809506B2 Antibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders 有权
标题翻译：用于α-突触核蛋白相关疾病的治疗和诊断方法的抗体和疫苗
公开(公告)号：US08809506B2
公开(公告)日：2014-08-19
申请号：US12990226
申请日：2009-04-28
申请人： Lars Lannfelt , Joakim Bergström , Martin Ingelsson , Pär Gellerfors
发明人： Lars Lannfelt , Joakim Bergström , Martin Ingelsson , Pär Gellerfors
IPC分类号： A61K39/395 , C07K16/18 , G01N33/567 , A61K38/17 , G01N33/68
CPC分类号： A61K51/1018 , A61K38/1709 , C07K16/18 , C07K2317/92 , G01N33/6896 , G01N2333/4709 , Y10S530/839
摘要： A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody.
摘要翻译：用于延迟个体中α-突触核蛋白相关病症的发作或治疗的疫苗包含治疗有效量的分离的稳定的可溶性α-突触核蛋白寡聚体，其具有比非可溶性聚集形式低的形成速率，稳定的α-突触核蛋白的寡聚物。用于延迟个体中α-突触核蛋白相关病症的发作或治疗的抗体结合可溶性α-突触核蛋白。用于延迟治疗或预防α-突触核蛋白相关病症的方法使用疫苗或抗体。 α-突触核蛋白寡聚物检测方法采用抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式